Potential human, environmental and ecological health effects associated with exposure to chemical, particularly those from hazardous waste sites is of great concern. However, tools for establishing the relationship between exposure and health effect are lacking. The long term goal of this project is to provide sensitive, selective, rapid and cost-effective immunoassay methods for monitoring human and environmental exposure to hazardous chemicals. The first of four objectives is to develop and validate single compound, as well as class selective immunoassays for urinary metabolites of hazardous compounds for use a biomarkers of internal exposure to these compounds. The objectives primary focuses on products of secondary metabolism, mercapturate, glucuronide and amino acid conjugates. The hazardous chemical classes that are targeted are the triazine herbicides, organophosphate and pyrethroid insecticides, and polycyclic aromatic hydrocarbons. Mercapturate and glucoronide conjugates are present in the urine from many sources, particularly food consumption. To separate """"""""naturally- occurring"""""""" conjugates from those derived from xenobiotic exposure, class selective antibodies to mercapturates and glucoronides will also be developed for use in immunoaffinity purification schemes implement immunoassays for parent compounds. The target compounds are dioxin, pyrethroid insecticides and technologies as they relate to immunoassays. Development of biosensors designed for use with immunoassays, improved collaborative with other projects in the UCD Superfund Program. Urinary biomarkers of exposure will be validated using low dose exposure studies and monitoring with accelerator mass spectrometry. Validate immunoassays and cell-relationship between exposure and effect to compounds such as TCDD, pyrethroid insecticides and octyl/nonyl phenol and bisphenol A. The ultimate goal of this project is to transfer this technology to other users by providing reagents training and support to other users.

Project Start
2002-09-24
Project End
2003-03-31
Budget Start
Budget End
Support Year
16
Fiscal Year
2002
Total Cost
$165,230
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications